(AOF) – bioMérieux announces the appointment of two new leaders: Dr. Charles K. Cooper becomes executive director in charge of medical affairs while Céline Roger-Dalbert will be executive director in charge of research and development, effective March 1, 2024. They replace respectively Dr Mark Miller and François Lacoste who “have chosen to retire”. Charles K. Cooper is a graduate of Georgetown University School of Medicine (Washington, DC, United States). Since 2021, he has been medical director of Siemens Healthcare Diagnostics.
Charles K. Cooper also served as Becton Dickinson’s chief medical and scientific officer after spending 13 years with the U.S. Food & Drug Administration.
Céline Roger-Dalbert joined bioMérieux in August 2022 as vice-president R&D in charge of clinical operations and regulatory affairs. Holder of a master’s degree in biotechnology at the Catholic University of Lyon, she also spent 15 years at Becton Dickinson in management positions in research and development.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
